Santen and Merck Sign Licensing Agreement for Tafluprost Treatment for Glaucoma and Ocular Hypertension
Links shared publicly online about this topic.
- 2,109total visits
Santen and Merck Sign Licensing Agreement for Tafluprost Treatment for Glaucoma and Ocular Hypertension
Santen Pharmaceutical of Japan announced earlierthis week that it hadsigned a worldwide licensing agreement granting Merckexclusive rights to market
View full resource at eyedocnews.com
Tags: Heart Disease, High Blood Pressure, Glaucoma, Pharma, Merck & Co.
Most Recently Shared on April 17, 2009 at 2:58 pm By:
Discuss: Santen and Merck Sign Licensing Agreement for Tafluprost Treatment for Glaucoma and Ocular Hype.. http://tinyurl.com/dkksq2
Advertisement
